Genentech’s Post

Our Promise is our north star for ourselves, patients, and society. It builds upon our history of forging life-altering scientific breakthroughs and reminds us that we are on a bolder quest than ever before - to be courageous changemakers in solving the world’s most complex health challenges and improving the lives of all patients. http://spr.ly/6049V62k7

Season 5 of our podcast, Two Scientists Walk Into a Bar, is officially halfway through! We have 5 episodes to go.

Today, we reintroduced a first-of-its-kind therapeutic approach that provides an alternative to standard of care eye injections for wet age-related macular degeneration, a leading cause of blindness for people aged 60 and over in the U.S. This evolution of the Port Delivery Platform lays the foundation for future retinal advancements. Read the full announcement here: http://spr.ly/60449Y8DE

The FDA approved the prefilled syringe version of our medicine to treat wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. Together, these three retinal conditions affect around 3 million people in the U.S. and are among the leading causes of vision loss. The prefilled syringe is designed to provide retina specialists a ready-to-use option for simpler administration. Learn more: http://spr.ly/60489pado

In S5E04 of our podcast, Two Scientists Walk Into A Bar, antibody engineers Yan Wu and Paul Carter discuss initial obstacles they've faced in this challenging field, antibody engineering advances they're excited about, and how computational methods like AI will continue transforming antibody discovery and development. Listen to the full episode: http://spr.ly/6042gmjk4

A new episode of our podcast, Two Scientists Walk Into A Bar just dropped! Antibody engineers Yan Wu and Paul Carter join us to discuss all things antibodies – from initial obstacles in developing antibody therapies, to advances in antibody engineering that are creating new classes of medicines. Plus, they share their thoughts on how #ArtificialIntelligence and #MachineLearning will be game changers for optimizing antibody design and generating new therapeutic antibodies from scratch. Listen to the full episode here: http://spr.ly/6047gmjD9

Community trust must be earned through sustained presence and engagement beyond traditional settings. That is why earlier this month we extended our reach beyond the ASCO Annual Meeting conference halls and into the local Chicago community itself – catalyzing discussions and actions to address healthcare inequities where they will have the greatest impact. Over the course of the weekend, we connected with and inspired students at Chicago Collegiate Charter School to pursue careers in STEM, sponsored a health equity symposium in partnership with the American Cancer Society and The University of Illinois Cancer Center, convened patient advocates and LGBTQ community leaders and sparked conversations challenging ASCO attendees to ask bigger questions about health outcome disparities across zip codes. Learn more about our community-centered approach at the world’s largest cancer research conference: http://spr.ly/6044gYhd0 #ASCO24

Earlier this month, we were honored to welcome Congresswoman Nanette Barragán and her staff to our South San Francisco headquarters! During her visit, Congresswoman Barragán toured our Clinical Supply Center and engaged in insightful discussions with our leadership teams from research & early development, manufacturing, and our Chief Diversity Office. We had the opportunity to showcase our transformative research innovations and our commitment to advancing clinical trial diversity, health equity, and access to treatments. Congresswoman Barragán’s enthusiasm and curiosity for our initiatives were truly inspiring. We are grateful for her dedication to fostering an environment that promotes healthcare innovation and her unwavering commitment to creating a more equitable and inclusive future. Thank you, Congresswoman Barragán, for your time and invaluable insights. Together, we can make a difference! #Innovation #Diversity #HealthEquity #Research

As the personalized cancer treatment landscape evolves, biomarker testing is essential to ensure non-small cell lung cancer (NSCLC) patients can receive the treatment best suited for their disease. Our Global Head of Oncology & Hematology Drug Development, Charlie Fuchs, discusses the importance of biomarker testing and how a new treatment for ALK early-stage resected NSCLC may help give people with early stage #NSCLC much needed options: http://spr.ly/60445qWFI